skip to primary navigationskip to content
 

Caroline Trotter

Infectious disease epidemiology and the impact of immunisation

I am an infectious disease epidemiologist with a particular interest in vaccine evaluation. Most of my work is on human diseases, in particular meningococcal disease, but my research encompasses a range of other infections including rabies, pneumococcus, Hib, group B streptococcus, HPV, rotavirus, and norovirus. I use a variety of methods, including field studies, observational studies, mathematical modelling and cost-effectiveness. I enjoy addressing questions of direct relevance to vaccine and public health policy.

I  am a member of the Vaccine Impact Modelling Consortium (VIMC). I work with Public Health England's Immunisation Department and collaborate with the World Health Organisation. 

Click for details of Meningitis Research Foundation funded projects on cost-effectiveness of GBS vaccines, persistence of MenAfriVac, use of MenAfriVac in pregnant women and how people value benefits of vaccination.


Key Publications

Google Scholar - link to all publications

WHO Rabies Modelling Consortium (Corresponding authors Trotter CL, Hampson K). The potential impact of improved provision of rabies post-exposure prophylaxis in Gavi-eligible countries: a modelling study. Lancet Infectious Diseases, 2018, Nov 21. pii: S1473-3099(18)30512-7. doi: 10.1016/S1473-3099(18)30512-7

Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, Ronveaux O, Preziosi MP, Stuart JM. The impact of MenAfriVac in nine countries of the African meningitis belt, 2010-2015: an analysis of surveillance data. Lancet Infect Dis 2017, pii: S1473-3099(17)30301-8

Karachaliou A, Conlan AJ, Preziosi MP, Trotter CL. Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt. Clin Infect Dis. 2015;61 Suppl 5:S594-600. 

MenAfriCar Consortium. The diversity of meningococcal carriage across the African meningitis belt and the impact of vaccination with a group A meningococcal conjugate vaccine. J Infect Dis 2015.  doi: 10.1093/infdis/jiv211 

Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating the cost-effectiveness of universal ‘MenB’ (Bexsero) vaccination in England: a modelling study. BMJ2014  349 

Daugla DM, Gami JP,  Gamougam K, Naibei N, Mbainadji L, Narbé M,  Toralta J, Kodbesse B, Ngadoua C, Coldiron M, Ferman F, Page A-L,  Djingarey M,  Hugonnet S, Harrison OB, Rebbetts LS, Tekletsion Y, Watkins ER, Caugant DA,  Chandramohan D,  Hassan-King M, Manigart O, Nascimento M, Woukeu A,  Trotter C, Stuart JM, Maiden MCJ, Greenwood B. The impact of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad. Lancet 2014.383:40-7

Caroline Trotter

Dr Caroline Trotter

Principal Research Associate in Epidemiology

Group members: Andromachi Karachaliou, Laura Cooper

Plain English

I study how well current vaccines work on a population-level and whether and how we should use new vaccines.